Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In

This article was originally published in The Pink Sheet Daily

Executive Summary

Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.
Advertisement

Related Content

Micromet Reacquires Full North American Rights To Blinatumomab
Micromet Reacquires Full North American Rights To Blinatumomab
Taking a BiTE Out of Cancer: An Interview With Micromet CEO Christian Itin
Taking a BiTE Out of Cancer: An Interview With Micromet CEO Christian Itin
Biotechs Show Off Early-Stage Progress At AACR Meeting
Biotechs Show Off Early-Stage Progress At AACR Meeting
Call the Plumber: PIPE Logic is Leaky
Infinity Regains Rights To Its Lead Program
Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies
Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies

Topics

Advertisement
UsernamePublicRestriction

Register

PS069116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel